MINI FUTURE OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Bid/Ask 18:45:49 05/07/2024 BST | After market 19:34:55 | |||
| 8.57 EUR | -5.72% |
|
8.68 | +1.28% |
| Current month | -0.87% | ||
| 1 month | +6.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 8.57 | -5.72% |
| 04/07/24 | 9.09 | +3.77% |
| 03/07/24 | 8.76 | 0.00% |
| 02/07/24 | 8.76 | -2.99% |
| 01/07/24 | 9.03 | -1.53% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 06:45 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB39CC |
| ISIN | DE000JB39CC4 |
| Date issued | 17/10/2023 |
| Strike | 568 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 18.55 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.67 € |
|---|---|
| Lowest since issue | 7.6 € |
| Spread | 0.04 € |
| Spread % | 0.46% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3
USD
Average target price
468.3
USD
Spread / Average Target
-0.43%
- Stock Market
- Certificates
- Certificat
